LILRB4 and myeloid sarcoma: Given the potent inhibitory capacity of ILT3 on T cell activation and proliferation, upregulation of this immune inhibitory receptor on monocytes in IFN beta-treated MS patients may indeed represent a therapeutic mechanism that helps to prevent overshooting immune responses.